The impact of new crown oral drugs against the epidemic and vaccines

Author: Weiran

Merck's oral drug monupivir turns COVID-19 into flu

The biggest risk of the new crown is that the patient’s excessive occupation of medical resources leads to the breakdown of the medical system.

On October 1, Merck announced the interim analysis data of its new crown oral specific drug molnupiravir (monupivir) in the mild phase III MOVe-OUT study.

Note: At present, the strength of the evidence for the conclusion of the disclosed data is already high, and the early termination reflects the humanitarianism of the comfort group.

The trial analyzed 775 patients who were included in the MOVe-OUT trial, who were laboratory-confirmed with mild to moderate COVID-19 and had at least one risk factor related to the severity of the disease (such as obesity, age> 60 years, diabetes, and heart disease).

Merck claims that molnupiravir (monupivir) reduces the risk of hospitalization or death in all major subgroups.

Although molnupiravir (monupiravir) has an ideal effect on mild cases, it has a mediocre effect on severe patients.

Lower cost (1) In June 2021, Merck and the U.

Production capacity has increased rapidly: The structure of molnupiravir (monupivir) is relatively simple, and the synthesis is not difficult.

Merck is applying to various regulatory agencies around the world for early listing: Merck will submit an emergency use authorization application to the FDA as soon as possible, and it will also submit a listing application to regulatory agencies in other countries around the world as soon as possible

The effect of monupivir on the new crown vaccine, neutralizing antibodies and CXO

New crown oral drugs (monupivir) and vaccines and neutralizing antibodies have complementary effects on the prevention and control of the new crown epidemic, but monupivir will affect the sustainability of the new crown vaccine.

In addition, Monupivir, which is expected to become the first oral drug for the new crown, disclosed data showing that CXO's new crown drug orders have gradually entered the harvest period, and the marginal revenue of some CXO's new crown drugs will gradually decline

Vaccines are undoubtedly still the best means to prevent and control the new crown.

However, the market’s expectations of vaccine companies have changed.

In the next few months, the new crown oral drugs will successively announce phase three clinical data.

Pioneer Pharmaceuticals Prokrulamide has carried out a number of phase III clinical trials for inpatients/outpatients around the world (including the United States).

Source: China Merchants Securities

Neutralizing antibodies have excellent effects, but they require injections.